Synaptic Vesicle Trafficking Dysfunction Validation in Parkinson's Disease

Synaptic Vesicle Trafficking Parkinsons

Experiment Design: SVT-PD-001

Overview

This multi-phase study aims to validate the Synaptic Vesicle Trafficking Dysfunction Hypothesis in Parkinson's Disease by assessing vesicle dynamics in patient-derived neurons, correlating with genetic risk variants, and testing therapeutic interventions.

Hypothesis

Impaired synaptic vesicle trafficking is an upstream driver of dopaminergic neurodegeneration in PD, not merely a downstream consequence.

Study Design

Phase 1: iPSC-Derived Neuron Studies

Objective

Characterize synaptic vesicle dynamics in dopaminergic neurons derived from PD patients with different genetic backgrounds vs. healthy controls.

Methods

| Parameter | PD Cases | Controls |
|-----------|----------|----------|
| Total subjects | 30 | 15 |
| LRRK2 G2019S carriers | 10 | — |
| VPS35 D620N carriers | 5 | — |
| Idiopathic PD | 10 | — |
| Healthy controls | — | 15 |
| Age range | 50-75 years | 50-75 years |

Primary Endpoints

Synaptic Vesicle Trafficking Parkinsons

Experiment Design: SVT-PD-001

Overview

This multi-phase study aims to validate the Synaptic Vesicle Trafficking Dysfunction Hypothesis in Parkinson's Disease by assessing vesicle dynamics in patient-derived neurons, correlating with genetic risk variants, and testing therapeutic interventions.

Hypothesis

Impaired synaptic vesicle trafficking is an upstream driver of dopaminergic neurodegeneration in PD, not merely a downstream consequence.

Study Design

Phase 1: iPSC-Derived Neuron Studies

Objective

Characterize synaptic vesicle dynamics in dopaminergic neurons derived from PD patients with different genetic backgrounds vs. healthy controls.

Methods

| Parameter | PD Cases | Controls |
|-----------|----------|----------|
| Total subjects | 30 | 15 |
| LRRK2 G2019S carriers | 10 | — |
| VPS35 D620N carriers | 5 | — |
| Idiopathic PD | 10 | — |
| Healthy controls | — | 15 |
| Age range | 50-75 years | 50-75 years |

Primary Endpoints

Secondary Endpoints

Phase 2: Genetic Correlation

Objective

Correlate synaptic vesicle function with known PD genetic risk variants.

Genetic Variants to Assess

| Gene | Variant | Expected Effect |
|------|---------|-----------------|
| SV2C | rs1871678, rs6474359 | Altered vesicle filling |
| VPS35 | D620N | Impaired endosomal sorting |
| SYNJ1 | R258Q | Impaired endocytosis |
| DNAJC13 | R392H | Endosomal dysfunction |

Analysis

• Whole exome sequencing for all participants
• Polygenic risk score calculation
• Correlation with vesicle function parameters

Phase 3: Therapeutic Testing

Objective

Test whether enhancing synaptic vesicle trafficking improves dopaminergic neuron survival.

Compounds to Test

| Compound | Target | Dose | Duration |
|----------|--------|------|----------|
| R55 | Retromer stabilizer | 10 mg/kg IP | 4 weeks |
| Tetrabenazine | VMAT2 inhibitor | 25 mg/day PO | 4 weeks |
| DMSO (vehicle) | — | — | 4 weeks |

In vivo Model

• C57BL/6 mice, 8-10 weeks old, male
• MPTP-induced parkinsonism model (30 mg/kg IP, 5 days)
• Behavioral testing: cylinder, grid, rotarod

In vitro Model

• Primary midbrain cultures from E14.5 rat embryos
• Treatment with test compounds for 7 days
• Alpha-synuclein PFF addition (day 3)

Readouts

Phase 4: Biomarker Validation

Objective

Identify biomarkers for early detection of synaptic vesicle dysfunction in PD.

Candidate Biomarkers

| Biomarker | Source | Method |
|----------|--------|--------|
| SV2C | CSF | ELISA |
| VAMP2 | Plasma exosomes | Western blot |
| Synaptotagmin-1 | CSF | MSD |
| VMAT2 binding | Brain PET | [11C]DTBZ PET |

Validation Cohort

• 50 early-stage PD patients (Hoehn & Yahr 1-2)
• 50 healthy controls
• Longitudinal sampling at 0, 6, 12, 24 months

Statistical Analysis

Power Calculation

• 80% power to detect 30% difference in vesicle density
• Alpha = 0.05, two-sided
• Accounting for 20% dropout

Primary Analysis

• Mixed-effects model for repeated measures
• Covariates: age, sex, disease duration
• False discovery rate correction for multiple comparisons

Ethical Considerations

• IRB approval required for iPSC studies
• Informed consent for genetic testing
• Animal studies under IACUC protocol

Timeline

| Phase | Duration | Start | End |
|-------|----------|-------|-----|
| Phase 1 | 18 months | Month 1 | Month 18 |
| Phase 2 | 12 months | Month 12 | Month 24 |
| Phase 3 | 12 months | Month 18 | Month 30 |
| Phase 4 | 24 months | Month 24 | Month 48 |

Budget Estimate

| Item | Cost (USD) |
|------|------------|
| Personnel | $1,200,000 |
| iPSC generation | $400,000 |
| Animal studies | $300,000 |
| Biomarker assays | $200,000 |
| PET imaging | $250,000 |
| Misc | $150,000 |
| Total | $2,500,000 |

Expected Outcomes

Risk Mitigation

| Risk | Mitigation |
|------|------------|
| iPSC reprogramming failure | Use validated protocols, have backup lines |
| Insufficient biopsy material | Use hair follicles or blood for reprogramming |
| Compound toxicity | Dose-finding study in healthy mice first |
| Dropout | Build in 20% cushion in enrollment |

Cross-References

• [Parkinson's Disease](/diseases/parkinsons-disease) — Primary disease
• [VPS35 Gene](/genes/vps35) — VPS35 mutation
• [SNARE Proteins](/mechanisms/snare-protein-function) — Vesicle fusion
• [Synaptic Vesicles](/cell-types/synaptic-vesicle-neurons) — Synaptic function
• [Dopamine Transport](/mechanisms/dopamine-transport-parkinsons) — Dopamine release
• [Synuclein Pathology](/mechanisms/alpha-synuclein-pathology) — alpha-synuclein
• [MPTP Model](/models/mptp-parkinson-model) — Mouse model

References